UNSPSC 51111842: Degarelix

This classification denotes a gonadotropin releasing hormone inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SX0XJI3A11. European Medicines Agency schedules Degarelix in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27748. Degarelix generally arises in the molecular formula C82H103CLN18O16. The term DEGARELIX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3, 2002, list 48.) Most nations schedule degarelix under HS 29371900 and SITC 54154.

UNSPSC 51111842 Degarelix, a Commodity code, encompasses the supply of this specific gonadotropin-releasing hormone (GnRH) antagonist and related pharmaceutical products to state and local government health systems, correctional facilities, and public health agencies. State and local procurement under this code focuses on establishing framework agreements with manufacturers and wholesalers to ensure reliable supply of brand-name and generic pharmaceuticals at negotiated pricing, with vendors required to meet cGMP certification, FDA compliance, Drug Supply Chain Security Act (DSCSA) attestation, and wholesaler-network relationships. The issuing bodies are primarily multistate cooperative purchasing alliances and state health departments that aggregate demand across member jurisdictions—state agencies, counties, municipalities, and special districts—to achieve volume discounts and streamlined contracting.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities, including Oregon. The procurement structure requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and awards pricing based on competitiveness (75 percent weight), fixed pricing for the contract term (10 percent), compliance with administrative data formats and EDI capability (5 percent each), and agreement to a 3 percent administrative fee (5 percent). The contract term is two years for new respondents with optional extensions, and incumbent vendors' amendments extend through June 30, 2028. Vendors must maintain commercial general liability coverage of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000. Products awarded will be provided to wholesalers by May 15, 2026, with effective contract dates of July 1, 2026.